cannabisnews.com: The Cannabis Conundrum










  The Cannabis Conundrum

Posted by CN Staff on February 02, 2004 at 08:20:46 PT
By Bill Breen, Senior Writer 
Source: Fast Company  

As the founder of a British pharmaceutical company puts it, if it weren't called marijuana there would be an entire biotech business built around this plant. And that's just what's starting to happen (but not for the U.S. drug industry or the American patients these medicines might help).One night in late September, Ethan Russo stood before a classroom packed with students on the University of Massachusetts' Amherst campus, and asked how many of them had been through the popular secondary-school program known as Drug Abuse Resistance Education, or DARE.
Almost every hand in the audience went up. "Just as I thought," said Russo. "Well, we're going to hit that one head-on." He then cheerfully presented his version of what can only be described as a drug reeducation program.Russo is a physician specializing in child neurology and one of the world's pioneering investigators into the therapeutic uses of pot. A slight, preternaturally good-humored man, Russo exhibited an outsized knowledge of his subject. Sticking strictly to the botanical name, Cannabis sativa , he noted that the plant's effects on the mind and body were first recorded by the ancient Assyrians in 2200 BC. These days, cannabis is used, mostly illegally, to relieve the nausea that accompanies chemotherapy, stimulate the appetites of AIDS sufferers, prevent blindness induced by glaucoma, suppress migraine headaches, and reduce the pain and muscle rigidity that accompanies multiple sclerosis.Although nonprescription medications such as aspirin kill thousands of people every year, not a single death has ever been attributed to a cannabis overdose. The "therapeutic ratio" of marijuana is estimated to fall somewhere between 20,000 and 40,000--meaning it would take that many times a normal dose to kill you. If the drug is delivered as a pill or a spray (smoking just about anything is bad for you, after all), then Russo is unequivocal: "Cannabis is a safer medicine than almost all of the standard pharmaceuticals available today."As he spoke, Russo clicked through a dazzling slide show: verdant fields of cannabis covering the foothills of Morocco's Rif Mountains; Thailand's marijuana plants on steroids, taller than a NBA center. But the most compelling slide was of a homely, quart-sized bottle labeled "Cannabis Tincture," which seemed to symbolize this country's inconsistent attitude toward medical marijuana. The United States has at times embraced the cannabis plant and its products: From the mid-19th century up until the mid-20th century, cannabis was a mainstream medicine, listed in the U.S. pharmacopoeia. The company that marketed the bottle of tincture was none other than Eli Lilly, the $11 billion behemoth that today is best known for another mood-altering drug, Prozac.More recently, of course, the U.S. government has cast cannabis as a pariah drug. This past June, Karen Tandy, the first woman to head the Drug Enforcement Administration, declared that marijuana "has not been shown to have medical benefits."Ethan Russo and a small group of trailblazing doctors, scientists, and businesspeople hope to prove her wrong. Russo recently signed on as a senior medical adviser to GW Pharmaceuticals, a British biotechnology company that has conducted clinical trials of cannabis-based medicines on people suffering from multiple sclerosis and chronic pain. In a memorandum to the House of Lords' committee on science and technology, GW reported that a vast major- ity of its patients have indicated "significant alleviation" of at least one symptom, including pain, spasticity, and bladder problems; in some cases, it said, the improvement "has been sufficient to transform lives."This past May, GW inked a deal with the German pharmaceutical company Bayer Healthcare AG to market Sativex, a cannabis-laced oral spray that's used for treating severe neuropathic pain and multiple-sclerosis symptoms. Bayer, which agreed to market Sativex in the UK and Canada--and optioned rights for Europe--is betting that in the next few months, the first modern medicine made entirely of cannabis will pass muster with British regulators. GW estimates that the European market for Sativex could total $300 million to $400 million. "We're finding that cannabis medicines have enormous pharmacological capabilities and a unique capacity to attack, in a disease like MS, an entire range of symptoms," says Dr. Geoffrey Guy, GW's founder and chairman. "If it wasn't called marijuana, by now there would have been an entire biotech industry built around this plant."GW's breakthroughs have put Guy in the vanguard of the aboveground marijuana economy, a handful of pharmaceutical entrepreneurs who are racing to build a legal market for cannabis medicines in countries that accept the drug's therapeutic potential (read: Canada, New Zealand, Australia, and most of western Europe). If Guy's bet pays off, GW just might become the Eli Lilly of medical marijuana. "Cruel Hoax" or Solid Science? The push to develop plant-based and synthetic cannabinoid medicines has been building since the early 1990s, when researchers identified nerve receptors in the brain that are stimulated by marijuana's active ingredient, THC, as well as the natural body chemical that binds to those receptors. The discovery of an entirely new class of brain receptors and the neurotransmitters that act on them--the endocannabinoid system--proved to be an astounding development, opening a whole new area of therapeutics. Investigators believe that the system plays a critical role in mediating pain, appetite, movement, and memory. The giants of the drug industry, including Lilly, Merck, Pfizer, and Schering-Plough, are now hard at work in the lab, attempting to cook up synthetic versions of the 61 cannabinoid compounds found in marijuana plants. These are complex molecules with 21 carbons unique to cannabis, of which THC is the best known. Big Pharma has high hopes for these synthetics for the treatment of obesity, smoking, cancer pain, migraines, and MS symptoms. But such efforts are still in the early stages of development.Investigators believe that the system in the brain that is stimulated by marijuana also plays a critical role in mediating pain, appetite, movement, and memory. At the more controversial end of the aboveground marijuana economy, developers are using the plant itself instead of synthetic compounds. "At least in the near future, it seems extremely unlikely that one of these companies will come up with a single synthetic agent that's as widely applicable as a cannabis-based medicine," says Russo. GW is taking whole extracts from the marijuana plant and recombining them to produce drugs that treat specific ailments. This plant-based approach has enabled the company to develop and test Sativex in five years, at a price tag of about $60 million. It's a remarkable feat, considering that Big Pharma on average shells out $800 million on a new drug and can easily devote a decade or more to animal research and first-dose-in-man testing. GW did minimal animal testing, taking Sativex rapidly to controlled, double-blind human trials. "Something like 400 million people a year take cannabis in one form or another, and yet there's never been a recorded fatality from it," says Guy.But you won't find any commercial development of plant-based marijuana medicines being pursued in the United States. Andrea Barthwell, a deputy director in the White House Office of National Drug Control Policy and President Bush's point person on medical marijuana, says cannabis medicines aren't compatible with modern science. They do not constitute "a serious line of research," she says."The people who are advancing marijuana as a medicine are perpetuating a cruel hoax that exploits our compassion for the sick," Barthwell says. "They are using patients' pain and suffering in an attempt to change America's drug control policy. Marijuana is a crude plant product that most definitely is not a medicine."It's a curious statement, given that it seems to reflect neither the views of the international scientific community nor those of the government's own regulatory agencies. For one thing, the Food and Drug Administration is reviewing 139 new-drug applications involving botanical research products, so plant-based medicines certainly aren't anathema. As for cannabis, in 1999 the Institute of Medicine, working at the behest of the White House drug czar's office, issued a lengthy report that assessed the scientific evidence concerning potential medical uses of marijuana. Its preeminent recommendation: "Research should continue into physiological effects of synthetic and plant-derived cannabinoids."Barthwell, however, says that marijuana hasn't been standardized for pharmaceutical production. Nor is there any evidence, she says, that the plant's various compounds can be reliably produced in consistent concentrations. Clearly, she hasn't visited the world's most futuristic pot farm. Down on the Farm At a secret location in southeastern England, GW Pharmaceuticals has built what might well be the most high-tech pot palace on the planet. Surrounded by electrified razor wire, video cameras, and motion detectors, the greenhouse sprawls across more than an acre of land. At any one time, more than 15,000 marijuana plants are growing under its 14-foot ceiling, with its banks of lights. Inside is a sea of green, comprised of some of the world's most potent strains of pot: Hindu Kush, White Widow, Skunk, Northern Lights. Outside of the Netherlands, GW is the only commercial organization in Europe licensed to cultivate cannabis on this scale.GW's drug-development strategy is based on the belief that various components of the plant work to treat specific illnesses, and it is breeding plant strains in which different cannabinoids predominate. In addition to its THC variety, GW is cultivating a strain that consists almost entirely of cannabidiol, or CBD, which moderates the THC high and possesses no psychoactive effect of its own. CBD may be useful in treating neuropathic pain, inflammation, and central-nervous system conditions such as epilepsy. To date, three drugs have been tested in clinical trials: GW's high-THC variety, high-CBD, and Sativex, which is a 50-50 mix of the two.Geoffrey Guy's goal--to cultivate medical-grade pharmaceutical plants that produce a specific cannabinoid--has required him to raise the art of cannabis-breeding to a spectacular level. Guy's CBD-producing plant strain is unique. And every one of Guy's plants--whether it's a THC, CBD, or one of several other varieties--is completely uniform, with absolutely no genetic variation between each plant. In that respect, the greenhouse resembles a living factory, where the product takes exactly 14 weeks, from planting to harvest, to move down the assembly line."Our job is to find out, ahead of everyone else, what the cannabinoids do," says Guy. "To accomplish that, we grow into the plant the exact profile of the chemicals we want. We control our finished product by controlling the plant." Dressed Better Than a Banker Geoffrey Guy is a physician and a maverick entrepreneur who has previously launched two publicly traded pharmaceutical companies. On one day in his office in a high-security compound south of London, he was decked out in a double-breasted business suit, complete with a white handkerchief peeking above the breast pocket--people in the legal-cannabis business tend to dress better than bankers. Guy cracks that his favorite mind-altering drug is rugby. He claims never to have smoked anything, least of all pot: "I've brought 14 different drugs to market, and I've never taken any of those, either."Guy might be the only man in England who has the know-how and the political connections necessary to launch a cannabis-based pharmaceutical company and shepherd its products through the British regulatory system. Nineteen years ago, he founded Ethical Holdings, a pharmaceutical company that developed morphine products, which gave him real-world experience in winning controlled-drug licenses from Britain's Home Office. In 1990, he founded Phytopharm, a company that specialized in developing medicines from Chinese herbal remedies.Starting in the mid-1990s, patient groups in the UK--particularly the powerful Multiple Sclerosis Society--began lobbying for changes in the drug laws that would allow sick people to receive prescribed cannabis. Guy, who had been devouring the medical literature on marijuana, thought that if he could get dispensation from the government, he had the science-and-business wherewithal to develop an approved medicine from an illegal plant. His hunch paid off. In June of 1998, after months of meetings with Guy, the British government granted GW the license to cultivate and supply cannabis for research and drug development.Still, had Guy failed to come up with an alternative to smoking cannabis, regulators never would have allowed him to proceed. For Sativex, GW has devised a delivery device that looks like a breath spritzer: Patients spray the drug onto the lining of the mouth; it takes effect within 20 to 45 minutes. The device allows patients to determine how many doses they need to relieve their symptoms. They tend to settle out at relatively modest levels--on average, 8 to 10 sprays of Sativex a day--which appear to be enough to relieve their symptoms without incurring an intoxicating effect. "These people are suffering from a terribly debilitating disease," says Guy. "They're just looking for a safe, efficacious medicine that will help them get on with their lives."For the U.S., a Missed Market? While the United Kingdom seems to be on the verge of approving Sativex--and countries from Canada to Australia are permitting the compassionate use of marijuana for seriously ill people--medical marijuana research remains mired in politics in the United States. California has established the Center for Medicinal Cannabis Research at the University of California at San Diego, and the National Institute on Drug Abuse has implemented a mechanism for supplying marijuana to the center's investigators. (Scientists outside of California who aspire to investigate medical marijuana face a torturous regulatory approval process.) Thus far, federal regulators have approved 14 of the center's studies. One such study is investigating the short-term effects of cannabis on spasticity in 30 MS patients. Meanwhile, GW has just completed phase III clinical trials on more than 1,000 patients--the largest program of clinical research on cannabis ever.In September, a California physician who had just returned from a two-day conference of the International Association of Cannabis as Medicine at Germany's University of Cologne--which brought together the world's best minds in the field--bemoaned this country's stunted research environment. "It is frustrating to watch the advancements in research on cannabis and cannabinoids taking place that we here in the USA can only dream of," he wrote in a well-circulated email. "The dark ages of medicine and science imposed by the American disease, prohibitionism, is painfully apparent."If Geoffrey Guy realizes his dream, Sativex will simply be the first of many such drugs to sweep through Europe and Canada. Meanwhile, the politics of pot insure that cannabis-based medicines will remain out of reach for U.S. patients and the U.S. pharmaceutical industry alike.Bill Breen is a Fast Company senior writer. He did no product sampling in reporting this story.Source: Fast Company (NY)Author: Bill Breen, Senior WriterPublished: February 2004 - Issue 79 - Page 82Copyright: 2004 Gruner and Jahr USA PublishingContact: loop fastcompany.comWebsite: http://www.fastcompany.com/DL: http://www.fastcompany.com/magazine/79/cannabis.htmlRelated Articles & Web Site:GW Pharmaceuticalshttp://www.gwpharm.com/British Firm Holds Hope for Users of Medical Pothttp://cannabisnews.com/news/thread18277.shtmlBritain To Approve Medicine Derived From MJhttp://cannabisnews.com/news/thread18224.shtmlLittle Light Confusion Over Cannabis Drug Date http://cannabisnews.com/news/thread18194.shtml

Home    Comment    Email    Register    Recent Comments    Help






 


Comment #20 posted by charmed quark on February 03, 2004 at 14:36:50 PT

Absorption of Sativex
Thanks, Max Flowers. I remember now that this sublingual approach was mentioned when Russo had the online discusion. I assume that this absoption by the mucosa means it goes directly into the blood stream and bypasses liver processing, the same as inhaled cannabinoids?I wonder how long you have to let it sit under your tongue before you can swallow. Is there a carrier to speed absorpton?It seems lke this approach is half way between the oral pill form and smoking. But it still takes 25 to 40 minutes to work. That would make it hard to titrate the dosage.Too bad they can't come up with a minature vaporizer and administer it that way.-Pete

[ Post Comment ]


 


Comment #19 posted by E_Johnson on February 03, 2004 at 10:06:38 PT

Dr. Russo
I was so upset by Guy yet again pandering to the public prejudice that smoking marijuana makes people mentally disabled that I stayed up late working really hard to prove I'm not disabled.I got a lot done but now I'm tired. There are many advantages to a standardized, pharmacy-friendly cannabinoid medication that can be promoted to the public without claiming that people who use the raw herb are mentally disabled by it.I hope I don't have to hear that kind of noise coming from GW any more because I do take it personally. I work very hard and I am proud of my accomplishments. My accomplishments while using raw marijuana include completing a Ph.D., writing a book and founding an online school.If that's disability then everyone should be so disabled.Guy could tell his patients, "No, don't use raw marijuana, or you'll end up disabled like HER -- with a Ph.D., a book and her own school."I really am sensitive to this. I hope he changes his line. The products can be promoted just fine without making the competition out to be stupid.The government is out there every day calling us all stupid.It hurts to have the same line repeated and pandered to by someone who says he's trying to help.
[ Post Comment ]


 


Comment #18 posted by FoM on February 03, 2004 at 09:44:20 PT

schmeff 
I just look at issues differently and I understand how people feel. I won't defend or condemn GWPharm. That's not my nature.
[ Post Comment ]


 


Comment #17 posted by schmeff on February 03, 2004 at 09:36:29 PT

Sativex & Drug Testing
I don't see how the approval of Sativex would affect the drug testing industry one way or another. There are prescription opiate drugs that will show up on a drug scan...if you can produce a doctor's prescription to explain the the positive results, you're in the clear.If you show positive for THC after a drug test, I expect the sponsor of said test will expect you to produce your bona fide Sativex Rx, or Marinol Rx or face the consequences. If Marinol hasn't negatively impacted drug testing, why would Sativex?As for forfeiture: it is a sleazy, scum-sucking, Patriot Act-like, unconstitutional abuse of government power. In my state we have prohibited (through the initiative process) the forfeiture of private property unless a person is CONVICTED of a crime.
[ Post Comment ]


 


Comment #16 posted by Max Flowers on February 02, 2004 at 15:32:03 PT

charmed quark
Neither, it is absorbed by the oral mucosa.
[ Post Comment ]


 


Comment #15 posted by charmed quark on February 02, 2004 at 15:12:34 PT

The plant stuff does work better
My third day of migraine. The Marinol (THC) that I use nearly everyday as a preventative for my migranes, wasn't working. I was reaching the point of being totally disabled by the migrane, so I broke out the natural form just a few minutes ago. Maybe the forth time in the lat year.The stuff has a relatively high CBD/THC ratio. That seems to work best. Incredible. One puff and my migraine has evaporated. No migraine abortant I have ever taken works like this.And it works much better than the Marinol(which is still the best legal drug I have used for migranes).I have a question for Dr. Russo - does Sativex get ingested or does it go into the lungs? I ask because I know ingesting
CBD converts into a cannabinoid that causes a sedating effect, but through the lungs it has no psychoactive effect but still has strong antiimflammatory and nuroprotective effects.-Pete
[ Post Comment ]


 


Comment #14 posted by FoM on February 02, 2004 at 14:42:26 PT

schmeff
I thought of another reason that I think the way I do. If messing up drug testing and stopping forfeiture is what could happen because of GWPharms push then we will win. Laws against cannabis are what holds the drug war together I think.Take the money out and we will win. That's why Sativex or medical mariuana are both fine with me.
[ Post Comment ]


 


Comment #13 posted by Rev Jonathan Adler on February 02, 2004 at 14:01:09 PT:

Legal Distribution coming in Hawaii!
Ethan, Aloha and GW scored when they snapped him up!
Hawaii now has two bills (HB2669 and SB3139) that we generated in our legislature which are the first step towards legal distribution in the United States. This is landmark stuff! If this bill is passed and signed in, wow!
I hope Dr. Russo and GW's Dr. Guy will support our intentions to enter the marketplace in Hawaii! The patients and doctors have cried out for a legal source here for three years during which all registered patients had to break the law to even get seeds or clones, much less phyto-sanitary med-grade cannabis. This bill allows us also to treat "ice" addicts with medical cannabis also. Please help us to make it happen! There should be a nation-wide coordination of activists to lobby this bill through! Let's make history!
Hawaii Medical Marijuana Institute
[ Post Comment ]


 


Comment #12 posted by goneposthole on February 02, 2004 at 12:59:34 PT

smoke some
Smoking cannabis is ok, too. Roll it into joints. Put some in a pipe and light it with a match or lighter. It is proven beyond any measure of doubt to have an efficacious pleasantness. Few disagree.Funny how cigarettes can be sold by the billions the world over in pre-rolled form in packages. That's ok. Stockholders, billion dollar industries, the whole nine yards. All you can get lollapalooza for tobacco.Cannabis is grown in secret locations. Prior conditions must be met on the method of delivery. Horsefeathers. You can smoke it too.
[ Post Comment ]


 


Comment #11 posted by FoM on February 02, 2004 at 12:25:11 PT

schmeff 
I know what you mean. I really do understand. What about how it will help with drug testing. I'm not into pharmaceuticals or hard drugs legal or illegal but how it might effect drug testing interests me. Hopefully cannabis will be rescheduled. If that happens the penalties would drop and even forfeiture laws might need to change. I look at different things I guess.
[ Post Comment ]


 


Comment #10 posted by E_Johnson on February 02, 2004 at 12:18:16 PT

Treeanna do you you like being called disabled?
"Regretful as it may be, the legitimization of this medicine by its commercialization is probaly the best hope we have.
"It's not the fact of commercialization that I mind.I mind being called disabled by a man who himself has never experienced -- HE THINKS -- the subjective mental state he keeps deriding.Guy gets his cannabinoid high from exercise. But he doesn't consider that disabling? It's the same thing. He just won't admit it. He is a stoner. But he is a virtuous Victorian upper class stoner who gets high from manly exertion. From doing work. The Puritan work ethic.Never mind if his exercise is purely recreational and does nothing to benefit anyone but himself. It's work, it's not getting high! It's good, not evil.No, we are the evil ones. By his implication.I would like to believe that cannabinoid medications can be marketed successfully without making ignorant and untruthful public statements about the "disability" caused by using strains and delivery methods other than GW's.This presumed "disability" is a pseudoscientific belief that stems mainly from racial and class prejudice.It would really appall me to no end if cannabinoid meidcations end up being marketed with a strategy that plays into racial and class prejudice.There really are moral choices here that are meaningful to the welfare of all. I trust Dr. Russo to make the right choices but I do not trust the man who employs him.Sorry but that's the way it is.
[ Post Comment ]


 


Comment #9 posted by schmeff on February 02, 2004 at 12:10:04 PT

You can make aspirin from willow bark, but...
FOM, I guess we do have a choice to make our own aspirin, but if we are burdened by more severe pain, we do not have the choice to make codeine from poppys.This is what I fear from the success of Sativex: a theft of our collective property to fuel proftits for the few."Our job is to find out, ahead of everyone else, what the cannabinoids do," says Guy. "To accomplish that, we grow into the plant the exact profile of the chemicals we want. We control our finished product by controlling the plant."It really is about control. GW gets to "find out", and profit from, a plant that the Creator GAVE TO US, because of a controlled playing field. "To accomplish that," it must be made illegal, or nearly impossible, for anyone else to conduct similar research. Yes, it's great that people who need relief may find relief, but don't expect anyone to get the choice of producing THEIR OWN relief. 
[ Post Comment ]


 


Comment #8 posted by Treeanna on February 02, 2004 at 11:43:12 PT

Great!
I am very glad that Dr. Russo is there for us to keep a pulse on the company and to promote serious consideration of cannabis and derivatives as a medicine by the mainstream.Regretful as it may be, the legitimization of this medicine by its commercialization is probaly the best hope we have.
[ Post Comment ]


 


Comment #7 posted by SystemGoneDown on February 02, 2004 at 11:11:04 PT

Connection
I read that George. W and George Bush were large stock holders for the Lily pharmecuetical corporation when the "Just Say No" campaign was kicked off by Reagan.
[ Post Comment ]


 


Comment #6 posted by E_Johnson on February 02, 2004 at 10:15:57 PT

I don't LIKE being called disabled!!
Dr. Russo, can you tell your boss that I am not disabled by my medicine and I feel insulted and threatened every time he makes this accusation as part of his marketing strategy.
[ Post Comment ]



 


Comment #5 posted by FoM on February 02, 2004 at 09:24:15 PT

Dr. Russo
How I see GWPharm is a company that has the money to get Cannabis in a spray form to many people. I was telling my husband that if I could make my own aspirin by using white willow bark and what ever else is needed I could do it or buy aspirin. This is a choice. If this gets approved in the U.S. it will play havoc wih the drug testing industry. 
[ Post Comment ]



 


Comment #4 posted by Ethan Russo MD on February 02, 2004 at 09:16:08 PT

GW Pharmaceuticals and Morality
I will comment briefly, and yield the floor to others.I am Senior Medical Advisor to GW Pharmaceuticals. At no time during the almost 6 years that I have been associated with this company have I ever been asked to say, do, plan or execute anything that has disturbed my moral compass. This is an organization filled with serious persons motivated by a desire to restore cannabis to its rightful place in the pharmacopoiea, and make it available to millions of desperately ill people around the world. Yes, they hope it to be profitable. If that is a sin, many are similarly tainted.No one has any illusions that the desire of certain people to cultivate and utilize their own cannabis will disappear as a result of the pharmaceutical development of Sativex, and products in the pipeline. Any legislative initiatives affecting cannabis will originate from political sources, and not the company. With all due deference to my many patients, friends and acquaintances who utilize clinical cannabis, it is sometimes the case that they do not realize that there is a tremendous reservoir of extremely ill people in the world that would no more consider smoking cannabis or in any way entering into black market commerce than they would volunteer for the first manned mission to Mars. Many patients seek a pharmaceutical grade product that their doctor can prescribe for them, and for which they can receive HMO or national health insurance coverage. Such a medicine will need to be standardized, safe, and of proven efficacy. With rare exceptions in certain countries, it is unlikely to be in the form of a joint.I am proud to be associated with this company, and in some small part with this advancement of cannabis therapeutics.
[ Post Comment ]



 


Comment #3 posted by Virgil on February 02, 2004 at 09:06:16 PT

Barfwell cannot let it go, can she? 
Any story we have to amplify on the GW extracts is big news. It just shows the Nazis thing their defenses can hold. What is funny is how they are talking about growing medicines on commercials. Unbelievable.The thing that I will want to see is Bayer commercials in the UK. When you have a wonder product like that with no lasting side effects, how can you not brag. Remember how Viagra raised the level of advertising for new patent medicines? It would be nothing for Bayer to spend $50 million on advertising GW extracts this year. The Barfwell boilerplate tells a sad tale for this country. That she says what she says and knowing what I know, makes me sad for America. The only thing that will cure that sadness is Free Weed.
[ Post Comment ]



 


Comment #2 posted by E_Johnson on February 02, 2004 at 08:46:55 PT

How will he pay his karmic debts Dr. Russo?
Guy owes everything he has to the community of lawbreakers who developed this plant into the state where he could start his own company based on its powers.He better not sound too morally superior to the marijuana community when he's running around promoting himself and his products.Because karmic debts have a way of being collected in ways people don't even expect or see coming.
[ Post Comment ]



 


Comment #1 posted by FoM on February 02, 2004 at 08:21:50 PT

Virgil
Here's the article you wanted to see about Dr. Russo and GWPharm! Way to go Dr. Russo!
[ Post Comment ]






  Post Comment